Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial
Background To compare intermittent treatment (IT) versus continuous treatment (CT) using cyproterone acetate (CPA) in bone metastatic prostate cancer patients, we conducted an open-label, multicenter randomized trial. Continuous androgen deprivation therapy is the standard treatment in metastatic pr...
Gespeichert in:
| Veröffentlicht in: | World journal of urology 2014-10, Vol.32 (5), p.1287-1294 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1294 |
|---|---|
| container_issue | 5 |
| container_start_page | 1287 |
| container_title | World journal of urology |
| container_volume | 32 |
| creator | Verhagen, Paul C. M. S. Wildhagen, Mark F. Verkerk, Annet M. Vjaters, Egils Pagi, Hembo Kukk, Leonhard Bratus, Dejan Fiala, Richard Bangma, Chris H. Schröder, Fritz H. Mickisch, Gerald H. J. |
| description | Background
To compare intermittent treatment (IT) versus continuous treatment (CT) using cyproterone acetate (CPA) in bone metastatic prostate cancer patients, we conducted an open-label, multicenter randomized trial. Continuous androgen deprivation therapy is the standard treatment in metastatic prostate cancer. Intermittent treatment might maintain efficacy while toxicity and costs are reduced.
Methods
Patients received CPA 100 mg tid in the prephase. Patients with a PSA decline of ≥90 % or PSA |
| doi_str_mv | 10.1007/s00345-013-1206-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1566109715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3443066361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-439f8915c49a38f4074cb788512eb619fba95d48a7532c4de88242a5997b14cc3</originalsourceid><addsrcrecordid>eNp1kU9r3DAQxUVoSLbbfIBcgqCXXNzqryXlFpa0XVjoJT0LWR4HL7acSHJh--kjZ9NQAj1Jo_nN0zweQpeUfKGEqK-JEC5kRSivKCN1RU7QigrOK61Y_QGtiGKiEkbzc_QxpT0hVNVEnqFzJpjUnPIVytuQIY59zhAy_g0xzQn7KeQ-zNNyPTzGqRBTAOw8ZJcB9wE3Sz2WMpWX3uMCpZeed8FDvMER0jzkhKcOOxxdaKex_wMtzrF3wyd02rkhwcXruUa_vt3db35Uu5_ft5vbXeWFYLkS3HTaUOmFcVx3gijhG6W1pAyampqucUa2QjslOfOiBa2LMSeNUQ0V3vM1uj7qlvWeZkjZjn3yMAwuQDFnqaxrSoyisqCf36H7aY6hbLdQkivOa10oeqR88ZsidPYx9qOLB0uJXSKxx0hsicQukVhSZq5eledmhPZt4m8GBWBHIJVWeID4z9f_VX0GHZaXjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1565373368</pqid></control><display><type>article</type><title>Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Verhagen, Paul C. M. S. ; Wildhagen, Mark F. ; Verkerk, Annet M. ; Vjaters, Egils ; Pagi, Hembo ; Kukk, Leonhard ; Bratus, Dejan ; Fiala, Richard ; Bangma, Chris H. ; Schröder, Fritz H. ; Mickisch, Gerald H. J.</creator><creatorcontrib>Verhagen, Paul C. M. S. ; Wildhagen, Mark F. ; Verkerk, Annet M. ; Vjaters, Egils ; Pagi, Hembo ; Kukk, Leonhard ; Bratus, Dejan ; Fiala, Richard ; Bangma, Chris H. ; Schröder, Fritz H. ; Mickisch, Gerald H. J.</creatorcontrib><description>Background
To compare intermittent treatment (IT) versus continuous treatment (CT) using cyproterone acetate (CPA) in bone metastatic prostate cancer patients, we conducted an open-label, multicenter randomized trial. Continuous androgen deprivation therapy is the standard treatment in metastatic prostate cancer. Intermittent treatment might maintain efficacy while toxicity and costs are reduced.
Methods
Patients received CPA 100 mg tid in the prephase. Patients with a PSA decline of ≥90 % or PSA <4 ng/ml were randomized. If patients were progressive, LHRH analogues were added. Primary end point was time to PSA progression.
Results
A total of 366 patients were recruited; 258 reached a good response after 3 or 6 months and were randomized. A total of 131 patients randomized to IT and 127 to CT. Patients on IT had an average of 1.7 episodes on CPA, before LHRH analogues were started. The mean time without treatment in IT was 463 days versus 422 days on treatment. There were statistical significant differences between IT and CT in 3 of the 5 functional scales of EORTC QLQ C 30; however, the clinical relevance of this finding appears modest. Symptom and potency scales showed significant advantages for IT. There were no differences in time to PSA progression on CPA, time to PSA and/or clinical progression on LHRH analogues and time to cancer-specific and overall survival.
Conclusions
IT by CPA is associated with less symptoms and modest advantages in QOL domains. There were no differences in time to PSA progression, clinical progression or survival.</description><identifier>ISSN: 0724-4983</identifier><identifier>EISSN: 1433-8726</identifier><identifier>DOI: 10.1007/s00345-013-1206-0</identifier><identifier>PMID: 24258313</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Androgen Antagonists - administration & dosage ; Bone Neoplasms - drug therapy ; Bone Neoplasms - secondary ; Cyproterone Acetate - administration & dosage ; Humans ; Male ; Medicine ; Medicine & Public Health ; Nephrology ; Oncology ; Original Article ; Prostatic Neoplasms - pathology ; Urology</subject><ispartof>World journal of urology, 2014-10, Vol.32 (5), p.1287-1294</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><rights>Springer-Verlag Berlin Heidelberg 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-439f8915c49a38f4074cb788512eb619fba95d48a7532c4de88242a5997b14cc3</citedby><cites>FETCH-LOGICAL-c442t-439f8915c49a38f4074cb788512eb619fba95d48a7532c4de88242a5997b14cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00345-013-1206-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00345-013-1206-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24258313$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verhagen, Paul C. M. S.</creatorcontrib><creatorcontrib>Wildhagen, Mark F.</creatorcontrib><creatorcontrib>Verkerk, Annet M.</creatorcontrib><creatorcontrib>Vjaters, Egils</creatorcontrib><creatorcontrib>Pagi, Hembo</creatorcontrib><creatorcontrib>Kukk, Leonhard</creatorcontrib><creatorcontrib>Bratus, Dejan</creatorcontrib><creatorcontrib>Fiala, Richard</creatorcontrib><creatorcontrib>Bangma, Chris H.</creatorcontrib><creatorcontrib>Schröder, Fritz H.</creatorcontrib><creatorcontrib>Mickisch, Gerald H. J.</creatorcontrib><title>Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial</title><title>World journal of urology</title><addtitle>World J Urol</addtitle><addtitle>World J Urol</addtitle><description>Background
To compare intermittent treatment (IT) versus continuous treatment (CT) using cyproterone acetate (CPA) in bone metastatic prostate cancer patients, we conducted an open-label, multicenter randomized trial. Continuous androgen deprivation therapy is the standard treatment in metastatic prostate cancer. Intermittent treatment might maintain efficacy while toxicity and costs are reduced.
Methods
Patients received CPA 100 mg tid in the prephase. Patients with a PSA decline of ≥90 % or PSA <4 ng/ml were randomized. If patients were progressive, LHRH analogues were added. Primary end point was time to PSA progression.
Results
A total of 366 patients were recruited; 258 reached a good response after 3 or 6 months and were randomized. A total of 131 patients randomized to IT and 127 to CT. Patients on IT had an average of 1.7 episodes on CPA, before LHRH analogues were started. The mean time without treatment in IT was 463 days versus 422 days on treatment. There were statistical significant differences between IT and CT in 3 of the 5 functional scales of EORTC QLQ C 30; however, the clinical relevance of this finding appears modest. Symptom and potency scales showed significant advantages for IT. There were no differences in time to PSA progression on CPA, time to PSA and/or clinical progression on LHRH analogues and time to cancer-specific and overall survival.
Conclusions
IT by CPA is associated with less symptoms and modest advantages in QOL domains. There were no differences in time to PSA progression, clinical progression or survival.</description><subject>Aged</subject><subject>Androgen Antagonists - administration & dosage</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - secondary</subject><subject>Cyproterone Acetate - administration & dosage</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Urology</subject><issn>0724-4983</issn><issn>1433-8726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU9r3DAQxUVoSLbbfIBcgqCXXNzqryXlFpa0XVjoJT0LWR4HL7acSHJh--kjZ9NQAj1Jo_nN0zweQpeUfKGEqK-JEC5kRSivKCN1RU7QigrOK61Y_QGtiGKiEkbzc_QxpT0hVNVEnqFzJpjUnPIVytuQIY59zhAy_g0xzQn7KeQ-zNNyPTzGqRBTAOw8ZJcB9wE3Sz2WMpWX3uMCpZeed8FDvMER0jzkhKcOOxxdaKex_wMtzrF3wyd02rkhwcXruUa_vt3db35Uu5_ft5vbXeWFYLkS3HTaUOmFcVx3gijhG6W1pAyampqucUa2QjslOfOiBa2LMSeNUQ0V3vM1uj7qlvWeZkjZjn3yMAwuQDFnqaxrSoyisqCf36H7aY6hbLdQkivOa10oeqR88ZsidPYx9qOLB0uJXSKxx0hsicQukVhSZq5eledmhPZt4m8GBWBHIJVWeID4z9f_VX0GHZaXjQ</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Verhagen, Paul C. M. S.</creator><creator>Wildhagen, Mark F.</creator><creator>Verkerk, Annet M.</creator><creator>Vjaters, Egils</creator><creator>Pagi, Hembo</creator><creator>Kukk, Leonhard</creator><creator>Bratus, Dejan</creator><creator>Fiala, Richard</creator><creator>Bangma, Chris H.</creator><creator>Schröder, Fritz H.</creator><creator>Mickisch, Gerald H. J.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20141001</creationdate><title>Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial</title><author>Verhagen, Paul C. M. S. ; Wildhagen, Mark F. ; Verkerk, Annet M. ; Vjaters, Egils ; Pagi, Hembo ; Kukk, Leonhard ; Bratus, Dejan ; Fiala, Richard ; Bangma, Chris H. ; Schröder, Fritz H. ; Mickisch, Gerald H. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-439f8915c49a38f4074cb788512eb619fba95d48a7532c4de88242a5997b14cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Androgen Antagonists - administration & dosage</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - secondary</topic><topic>Cyproterone Acetate - administration & dosage</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verhagen, Paul C. M. S.</creatorcontrib><creatorcontrib>Wildhagen, Mark F.</creatorcontrib><creatorcontrib>Verkerk, Annet M.</creatorcontrib><creatorcontrib>Vjaters, Egils</creatorcontrib><creatorcontrib>Pagi, Hembo</creatorcontrib><creatorcontrib>Kukk, Leonhard</creatorcontrib><creatorcontrib>Bratus, Dejan</creatorcontrib><creatorcontrib>Fiala, Richard</creatorcontrib><creatorcontrib>Bangma, Chris H.</creatorcontrib><creatorcontrib>Schröder, Fritz H.</creatorcontrib><creatorcontrib>Mickisch, Gerald H. J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>World journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verhagen, Paul C. M. S.</au><au>Wildhagen, Mark F.</au><au>Verkerk, Annet M.</au><au>Vjaters, Egils</au><au>Pagi, Hembo</au><au>Kukk, Leonhard</au><au>Bratus, Dejan</au><au>Fiala, Richard</au><au>Bangma, Chris H.</au><au>Schröder, Fritz H.</au><au>Mickisch, Gerald H. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial</atitle><jtitle>World journal of urology</jtitle><stitle>World J Urol</stitle><addtitle>World J Urol</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>32</volume><issue>5</issue><spage>1287</spage><epage>1294</epage><pages>1287-1294</pages><issn>0724-4983</issn><eissn>1433-8726</eissn><abstract>Background
To compare intermittent treatment (IT) versus continuous treatment (CT) using cyproterone acetate (CPA) in bone metastatic prostate cancer patients, we conducted an open-label, multicenter randomized trial. Continuous androgen deprivation therapy is the standard treatment in metastatic prostate cancer. Intermittent treatment might maintain efficacy while toxicity and costs are reduced.
Methods
Patients received CPA 100 mg tid in the prephase. Patients with a PSA decline of ≥90 % or PSA <4 ng/ml were randomized. If patients were progressive, LHRH analogues were added. Primary end point was time to PSA progression.
Results
A total of 366 patients were recruited; 258 reached a good response after 3 or 6 months and were randomized. A total of 131 patients randomized to IT and 127 to CT. Patients on IT had an average of 1.7 episodes on CPA, before LHRH analogues were started. The mean time without treatment in IT was 463 days versus 422 days on treatment. There were statistical significant differences between IT and CT in 3 of the 5 functional scales of EORTC QLQ C 30; however, the clinical relevance of this finding appears modest. Symptom and potency scales showed significant advantages for IT. There were no differences in time to PSA progression on CPA, time to PSA and/or clinical progression on LHRH analogues and time to cancer-specific and overall survival.
Conclusions
IT by CPA is associated with less symptoms and modest advantages in QOL domains. There were no differences in time to PSA progression, clinical progression or survival.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>24258313</pmid><doi>10.1007/s00345-013-1206-0</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-4983 |
| ispartof | World journal of urology, 2014-10, Vol.32 (5), p.1287-1294 |
| issn | 0724-4983 1433-8726 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1566109715 |
| source | MEDLINE; SpringerLink (Online service) |
| subjects | Aged Androgen Antagonists - administration & dosage Bone Neoplasms - drug therapy Bone Neoplasms - secondary Cyproterone Acetate - administration & dosage Humans Male Medicine Medicine & Public Health Nephrology Oncology Original Article Prostatic Neoplasms - pathology Urology |
| title | Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T17%3A25%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intermittent%20versus%20continuous%20cyproterone%20acetate%20in%20bone%20metastatic%20prostate%20cancer:%20results%20of%20a%20randomized%20trial&rft.jtitle=World%20journal%20of%20urology&rft.au=Verhagen,%20Paul%20C.%20M.%20S.&rft.date=2014-10-01&rft.volume=32&rft.issue=5&rft.spage=1287&rft.epage=1294&rft.pages=1287-1294&rft.issn=0724-4983&rft.eissn=1433-8726&rft_id=info:doi/10.1007/s00345-013-1206-0&rft_dat=%3Cproquest_cross%3E3443066361%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1565373368&rft_id=info:pmid/24258313&rfr_iscdi=true |